Table 1.
Demographic Data of Patients Included in the Study
| Group 1 (NIH 0) | Group 2 (NIH 1) | Group 3 (NIH 2) | Group 4 (NIH 3) | |
|---|---|---|---|---|
| Characteristic | n = 14 | n = 9 | n = 16 | n = 10 |
| oGVHD severity | None | Mild | Moderate | Severe |
| Age, yrs | ||||
| Mean ± SD | 56.1 ± 9.6 | 48.4 ± 15.4 | 52.6 ± 14.0 | 52.6 ± 15.2 |
| Range | 38–73 | 25–69 | 28–74 | 24–69 |
| Female, n (%) | 5 (36) | 2 (22) | 7 (44) | 1 (10) |
| Primary diagnosis, n (%) | ||||
| NHL | 0 (0) | 1 (11) | 4 (25) | 1 (10) |
| MM | 2 (14) | 0 (0) | 0 (0) | 2 (20) |
| ALL | 0 (0) | 2 (22) | 3 (19) | 2 (20) |
| AML | 8 (57) | 3 (33) | 7 (44) | 3 (30) |
| MDS | 2 (14) | 0 (0) | 2 (13) | 0 (0) |
| CML | 1 (7) | 0 (0) | 0 (0) | 1 (10) |
| CLL | 0 (0) | 1 (11) | 0 (0) | 0 (0) |
| Other | 1 (7) | 2 (22) | 0 (0) | 1 (10) |
| HCT source, n (%) | ||||
| PB | 12 (86) | 9 (100) | 16 (100) | 10 (100) |
| BM | 2 (14) | 0 (0) | 0 (0) | 0 (0) |
| No. of HLA-mismatch, n (%) | ||||
| 1 | 1 (7) | 1 (11) | 2 (13) | 1 (10) |
| 2 | 0 (0) | 1 (11) | 2 (13) | 0 (0) |
| Unrelated donor, n (%) | 3 (21) | 5 (56) | 8 (50) | 5 (50) |
| Time elapsed between AHCT and ocular exam (mo) | ||||
| Mean ± SD | 82.7 ± 85.7 | 66.1 ± 50.8 | 88.9 ± 62.6 | 90.6 ± 68.7 |
| Range | 2–265 | 20–170 | 16–206 | 27–199 |
No statistically significant differences were detected in age or time elapsed since AHCT between the groups.